CervoMed (NASDAQ: CRVO) has recently received a number of price target changes and ratings updates:
- 8/20/2026 – CervoMed was given a new $7.00 price target by Roth Capital.
- 8/15/2026 – CervoMed was upgraded by Wall Street Zen from “strong sell” to “sell”.
- 8/13/2026 – CervoMed was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 8/12/2026 – CervoMed had its “buy” rating reaffirmed by HC Wainwright.
- 8/3/2026 – CervoMed was upgraded by Chardan Capital to “strong-buy”.
- 7/31/2026 – CervoMed was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
- 7/17/2026 – CervoMed had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 7/15/2026 – CervoMed had its “buy” rating reaffirmed by HC Wainwright.
- 7/9/2026 – CervoMed had its “buy” rating reaffirmed by HC Wainwright.
Insider Activity
In related news, Director Joshua S. Boger purchased 955,414 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were purchased at an average cost of $3.14 per share, with a total value of $2,999,999.96. Following the completion of the acquisition, the director directly owned 1,795,865 shares of the company’s stock, valued at approximately $5,639,016.10. The trade was a 113.68% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 35.80% of the company’s stock.
CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.
Featured Stories
- Five stocks we like better than CervoMed
- Moderna’s 177% Surge Has Investors Asking What Comes Next
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
Receive News & Ratings for CervoMed Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CervoMed Inc and related companies with MarketBeat.com's FREE daily email newsletter.
